| Literature DB >> 29849539 |
Anshul Singh1, Ashu Chaudhary1.
Abstract
We present an inclusive characterization of the unimetallic and heterobimetallic complexes of copper synthesized using CuCl2 and diamine (4-fluoro 1,2-phenylenediamine) resulting in monometallic complex which further undergoes treatment with organometallic dichlorides of group 4 and 14 in 1 : 2 molar ratio resulting in heterobimetallic complexes. These complexes thoroughly characterized using various physical, analytical, and spectroscopic techniques indicate square planar and distorted octahedral geometry for the synthesized unimetallic and heterobimetallic complexes, respectively. These complexes were evaluated for their antimicrobial efficacy against various bacterial and fungal strains while hepatoprotective activity was also examined in male albino rats.Entities:
Year: 2018 PMID: 29849539 PMCID: PMC5925014 DOI: 10.1155/2018/2467463
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1
Figure 1Proposed structure for heterobimetallic complex [Cu(C6H5N2F)2Sn2(CH3)4Cl2].
Bacterial screening data of the synthesized Cu(II) complexes (percent growth inhibition after 24 hrs at 28 ± 2°C).
| Complex |
|
| ||
|---|---|---|---|---|
| 500 ppm | 1000 ppm | 500 ppm | 1000 ppm | |
| [Cu(C6H7N2F)2]Cl2 | 6 | 8 | 6 | 7 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 12 | 15 | 10 | 12 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 10 | 11 | 8 | 10 |
| [Cu(C6H5N2F)2Si2(Ph)4Cl2] | 9 | 11 | 8 | 9 |
| [Cu(C6H5N2F)2Ti2(Cp)4Cl2] | 8 | 10 | 7 | 8 |
| [Cu(C6H5N2F)2Zr2(Cp)4Cl2] | 8 | 9 | 6 | 7 |
| Streptomycin | 17 | 18 | 15 | 17 |
Fungicidal screening data of the synthesized Cu(II) complexes (percent growth inhibition after 96 hrs at 25 ± 2°C, conc. in ppm).
| Complex |
|
| ||||
|---|---|---|---|---|---|---|
| 50 ppm | 100 ppm | 200 ppm | 50 ppm | 100 ppm | 200 ppm | |
| [Cu(C6H7N2F)2]Cl2 | 32 | 38 | 46 | 28 | 35 | 41 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 52 | 56 | 64 | 46 | 51 | 58 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 43 | 50 | 52 | 40 | 45 | 49 |
| [Cu(C6H5N2F)2Si2(Ph)4Cl2] | 40 | 46 | 49 | 37 | 41 | 45 |
| [Cu(C6H5N2F)2Ti2(Cp)4Cl2] | 38 | 42 | 44 | 35 | 38 | 40 |
| [Cu(C6H5N2F)2Zr2(Cp)4Cl2] | 36 | 40 | 43 | 33 | 35 | 37 |
| Bavistin | 91 | 100 | 100 | 89 | 98 | 100 |
Figure 2Bactericidal activity of the synthesized Cu(II) complexes.
Figure 3Fungicidal activity of the synthesized Cu(II) complexes.
Hepatoprotective activity of heterobimetallic complexes of Cu(II).
| Group of animals | Time in weeks |
| C.D at 5% | |||
|---|---|---|---|---|---|---|
| I | II | III | IV | |||
|
| ||||||
| Control | 0.85 ± 0.10 | 0.86 ± 0.79 | 0.73 ± 0.06 | 0.86 ± 0.69 | 2.74 | 0.018 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 1.32 ± 0.75 | 1.48 ± 0.38 | 1.56 ± 0.45 | 1.61 ± 0.18 | 15.1 | 0.071 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 1.46 ± 0.50 | 1.52 ± 0.08 | 1.75 ± 0.10 | 1.80 ± 0.08 | 46.8 | 0.084 |
| CCl4 | 1.80 ± 0.05 | 2.30 ± 0.60 | 2.75 ± 0.15 | 3.70 ± 0.41 | 55.2 | 0.315 |
|
| ||||||
|
| ||||||
| Control | 7.24 ± 0.23 | 6.87 ± 0.22 | 6.90 ± 0.25 | 7.08 ± 0.10 | 0.451 | 0.442 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 6.67 ± 0.25 | 6.44 ± 0.20 | 6.40 ± 0.30 | 6.30 ± 0.24 | 3.10 | 0.348 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 6.50 ± 0.16 | 6.39 ± 0.27 | 6.36 ± 0.25 | 6.15 ± 0.22 | 4.69 | 0.342 |
| CCl4 | 5.98 ± 0.24 | 5.20 ± 0.17 | 4.82 ± 0.29 | 4.19 ± 0.17 | 39.6 | 0.350 |
|
| ||||||
|
| ||||||
| Control | 4.68 ± 0.25 | 4.50 ± 0.20 | 4.50 ± 0.20 | 4.78 ± 0.30 | 0.45 | 0.376 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 4.23 ± 0.37 | 3.97 ± 0.17 | 3.75 ± 0.25 | 3.55 ± 0.20 | 4.49 | 0.366 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 3.72 ± 0.24 | 3.62 ± 0.40 | 3.60 ± 0.25 | 3.42 ± 0.17 | 1.61 | 0.416 |
| CCl4 | 3.50 ± 0.20 | 2.50 ± 0.25 | 1.97 ± 0.40 | 1.35 ± 0.12 | 414.9 | 0.405 |
|
| ||||||
|
| ||||||
| Control | 2.40 ± 0.81 | 2.35 ± 0.10 | 2.34 ± 0.73 | 2.30 ± 0.17 | 0.18 | 0.207 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 2.53 ± 0.14 | 2.53 ± 0.24 | 2.67 ± 0.19 | 2.57 ± 0.14 | 1.44 | 0.150 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 2.67 ± 0.19 | 2.73 ± 0.18 | 2.74 ± 0.31 | 2.79 ± 0.12 | 1.23 | 0.295 |
| CCl4 | 2.58 ± 0.10 | 2.62 ± 0.10 | 2.80 ± 0.16 | 2.80 ± 0.15 | 5.80 | 0.183 |
|
| ||||||
|
| ||||||
| Control | 0.45 ± 0.10 | 7.50 ± 0.24 | 7.78 ± 0.50 | 9.20 ± 0.20 | 12.9 | 0.598 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 11.55 ± 0.40 | 14.25 ± 0.35 | 13.90 ± 0.55 | 15.10 ± 0.35 | 56.10 | 0.580 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 13.0 ± 0.40 | 14.15 ± 0.24 | 14.32 ± 0.25 | 16.40 ± 0.65 | 52.61 | 0.602 |
| CCl4 | 16.80 ± 0.40 | 22.20 ± 0.80 | 25.76 ± 0.70 | 32.20 ± 1.0 | 245.7 | 1.160 |
|
| ||||||
|
| ||||||
| Control | 9.65 ± 0.65 | 9.85 ± 0.51 | 8.65 ± 0.20 | 8.40 ± 0.65 | 7.90 | 6.729 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 14.32 ± 0.27 | 14.82 ± 0.63 | 14.82 ± 0.79 | 15.93 ± 0.45 | 8.95 | 0.896 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 12.73 ± 0.62 | 13.24 ± 0.66 | 14.04 ± 0.52 | 14.42 ± 0.27 | 5.18 | 0.990 |
| CCl4 | 16.10 ± 0.30 | 20.90 ± 0.24 | 26.00 ± 0.43 | 33.40 ± 1.5 | 265.0 | 1.376 |
|
| ||||||
|
| ||||||
| Control | 9.67 ± 0.50 | 9.85 ± 0.50 | 8.65 ± 0.20 | 8.45 ± 0.64 | 7.75 | 0.728 |
| [Cu(C6H5N2F)2Sn2(Ph)4Cl2] | 12.85 ± 0.50 | 14.83 ± 0.52 | 14.06 ± 0.52 | 14.48 ± 0.30 | 5.18 | 0.985 |
| [Cu(C6H5N2F)2Sn2(CH3)4Cl2] | 13.40 ± 0.60 | 14.77 ± 0.43 | 14.87 ± 0.43 | 15.61 ± 0.42 | 8.95 | 0.886 |
| CCl4 | 16.10 ± 0.34 | 20.24 ± 0.24 | 25.00 ± 0.44 | 33.60 ± 1.46 | 263.5 | 1.278 |
Figure 4Graphical representation of various biochemical parameters: (a) total bilirubin, (b) total protein, (c) albumin, (d) globulin, (e) aspartate aminotransaminase, (f) alanine aminotransaminase, and (g) alkaline phosphatase as compared to the control.